Genetic determinants of response to warfarin during initial anticoagulation - Wikidata - awgldk - TriplyDB

Genetic determinants of response to warfarin during initial anticoagulation

Genetic determinants of response to warfarin during initial anticoagulation

http://www.wikidata.org/entity/Q34759038

about

Venous thromboembolic disease Role of regulatory agencies in translating pharmacogenetics to the clinics Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis Mining electronic health records: towards better research applications and clinical care Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin Pharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next Decade Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference.10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal.Rapid genotyping of single nucleotide polymorphisms influencing warfarin drug response by surface-enhanced laser desorption and ionization time-of-flight (SELDI-TOF) mass spectrometry.Warfarin pharmacogenomics Paving the Way to Personalized Genomic Medicine: Steps to Successful Implementation.Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study.Loss-of-function CYP2C9 variants: finding the correct clinical role for Type 2 diabetes pharmacogenetic testing Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing Recent advances in preventing stroke recurrence.A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants.Expectations, validity, and reality in pharmacogenetics.Prescribing warfarin appropriately to meet patient safety goals.Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.Genotype-based dosing algorithms for warfarin therapy: data review and recommendations.Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice.Integration of modern genetic knowledge and technology into public health in India.A Proposal for an Individualized Pharmacogenetic-Guided Warfarin Dosage Regimen for Puerto Rican Patients Commencing Anticoagulation Therapy.Abstractions for Genomics Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects.Recent advances in the use of opioids for cancer pain Positive selection in the chromosome 16 VKORC1 genomic region has contributed to the variability of anticoagulant response in humans CSI consensus statement on prosthetic valve follow up Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'.Copy number variants in pharmacogenetic genes.Pharmacogenomics: the genetics of variable drug responses.Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9.Genotype and risk of major bleeding during warfarin treatment.Cardiovascular pharmacogenomics and individualized drug therapy Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial.Pharmacogenetics of drug-metabolizing enzymes in US Hispanics.Warfarin dose requirement in Turkish patients: the influences of patient characteristics and polymorphisms in CYP2C9, VKORC1 and factor VII

P2860

Q24631121-6D0351F2-5AA4-4567-95D0-CD93157728D9 Q24652693-2DAFAEFF-C002-4126-9DD9-BC2F7798E4C7 Q27002899-37B869AD-EDE8-4D70-AE19-41112BBB3913 Q27026134-B1047C69-297C-4159-BE39-583893FE89DC Q27927409-F11D9752-A26E-4DA7-944D-D2D23C58F19B Q28276514-FBAC1936-03E2-4DC0-9619-3334FD62613D Q28392069-9AA9FC0E-B803-4CF3-BAAA-4882FBA15C53 Q28943308-DC39FEC3-AD3F-4067-A8F0-6C660903E458 Q30663685-3B655C30-4064-45C9-9DA6-E3AE61E689A1 Q33517162-1C76E8FF-6ECC-4CDF-9824-76A9988411F9 Q33523960-84D8BA49-076C-496D-94A8-14A9D2798B4A Q33561482-4CD93FE9-F4BD-4D61-8151-1B96193DD404 Q33602704-92B807CA-A287-4ED0-B6F7-B786DAC561AE Q33770184-AE3EFB12-6FDA-4918-84AF-4B67B088FBC1 Q33779389-08906534-04E9-4BB4-ACC2-AD88B5B6FE11 Q33813830-44D469F0-819E-4F05-B157-883CBE086DCA Q33873364-C1E373DD-9377-49B3-AE88-FB3D7F3B02E2 Q33921846-7DFB7E16-F6F5-4BEE-8B87-E2EE9FE03EE2 Q33926313-7CA1DC3C-B0EC-4D20-94D2-84F4B4598DC7 Q33932089-A989EB59-EBD1-4D6A-B934-9BCBA43EFA74 Q34061511-81FDB9C0-713C-43A1-8950-44537D49B363 Q34065133-9EA7EFC1-56E8-41B3-A742-332782DCC22E Q34131354-003B399E-B444-4EDE-A910-08BAFFF4B241 Q34204815-6395BD2D-876D-4734-96BB-A0EA8E4AA8DF Q34273608-C8E78200-6592-4D02-B3F9-B65900E9E48A Q34279994-978D2048-4441-4BB9-AD4E-B3C5D525EE39 Q34337948-6D9AA0CC-AAF6-44D1-9A07-36AFF8737245 Q34402967-9F80B1A4-AF8B-4263-9EAC-FC24269981BA Q34418203-BCBE42F1-DAD6-4427-91CC-579BFD2C0059 Q34534993-26368E9C-EA20-46A6-9106-FE2F6ED8C77E Q34574855-D97186AB-3903-4213-9AD9-F2A93A390D63 Q34609020-64C05FB7-D69E-4700-97ED-48C55B278DFC Q34975631-0D5D12B3-7FB6-4FDA-A229-EC1D0A050531 Q34976915-4F42AC2A-B7FB-432D-B477-B2239A08F65A Q34994877-42DE4D74-8E92-4949-A831-7C87AB1513DC Q35006973-DE02B02D-387A-443B-8547-917BE51D632E Q35025518-D30624E8-6646-42B2-ACE6-D4A620C00F29 Q35555922-EF92B640-527F-4073-A38D-4BA21FB43F9C Q35661209-A38B1CD6-E7A2-4758-9671-C86B672F4CCB Q35678294-B8D0A39C-6201-4BD2-9222-858CC0D4E480

P2860

Genetic determinants of response to warfarin during initial anticoagulation

http://www.wikidata.org/entity/Q34759038

description

2008 nî lūn-bûn

@nan

2008 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մարտին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

name

Genetic determinants of response to warfarin during initial anticoagulation

@ast

Genetic determinants of response to warfarin during initial anticoagulation

@en

Genetic determinants of response to warfarin during initial anticoagulation

@nl

type

label

Genetic determinants of response to warfarin during initial anticoagulation

@ast

Genetic determinants of response to warfarin during initial anticoagulation

@en

Genetic determinants of response to warfarin during initial anticoagulation

@nl

prefLabel

Genetic determinants of response to warfarin during initial anticoagulation

@ast

Genetic determinants of response to warfarin during initial anticoagulation

@en

Genetic determinants of response to warfarin during initial anticoagulation

@nl

P1433

Q34759038-F4565A5B-9FD5-4F87-8565-3D2E30114324

P1476

Q34759038-E00B0476-AF8B-43B2-823E-8D4851711C56

P2093

Q34759038-25A72EDD-0A1B-4F5C-8865-A263EFA86D39

Q34759038-4FCE6BAB-0D55-4195-A7C7-13A889F5DA61

Q34759038-67C2115D-BE6B-49A3-9D5C-6A53A350C020

Q34759038-90D3B5EE-13BA-4BEA-A901-49F69123CD4D

Q34759038-9E3B0A29-4FD6-4425-A31C-E969E235D57C

Q34759038-A4EDD0F7-5C4E-4503-B785-A367B3A48BFC

Q34759038-CFFFA0A2-9689-4FC0-BB17-707BF3FB3D21

Q34759038-F82BE22D-9E3B-4D21-B169-8CB5D7688CD5

P2860

Q34759038-0504E39A-D018-4BFB-89C1-44A516D4126A

Q34759038-054FBCF9-070F-4846-BEC1-C9CBB6C60C8E

Q34759038-063817EE-AFC3-4D29-97BA-57B822D2EAE6

Q34759038-1EABADCB-335E-4794-BCB8-7B0E65417B48

Q34759038-264684D1-B667-4954-8E74-4B99CE629B5E

Q34759038-268D751E-DB3D-41B8-A173-DB4E8C85D590

Q34759038-26C856C6-614F-451A-B348-E68A18579804

Q34759038-313F28E9-CB05-415B-80DD-EB445C69801B

Q34759038-4026433C-4856-4A1D-8A42-25E3BC1D9FFE

Q34759038-41C94170-FB1C-4EEC-B14E-71F51A968A16

P304

Q34759038-F644F851-1BC5-4213-9B3F-60B0BD599C83

P31

Q34759038-9819C686-45F4-4F3C-A83C-6CC81DEDA98D

P356

Q34759038-8DCFCBA5-2598-4890-84FF-D78B1BDFC9E7

P407

Q34759038-6FC20EC9-0447-4D90-ABD5-D5BC2CA54B4A

P433

Q34759038-26662C74-427B-4929-A7E2-25916257CF4B

P478

Q34759038-A4B0BF77-4B13-4347-A9BA-AA6016D5111A

P50

Q34759038-C17FDE63-48D6-42EF-A214-AD3E7DD26F19

P577

Q34759038-15CB2DAD-A2D7-4634-8FBF-3035D2DF7691

P698

Q34759038-857C1882-F338-4201-9AAC-533C2E319104

P921

Q34759038-7B90E401-CA40-4E20-9CC6-28242B0E8386

P932

Q34759038-6600E759-2B01-43FD-9530-D455E4F8096F

P356

P1433

The New England Journal of Medicine

P1476

Genetic determinants of response to warfarin during initial anticoagulation

@en

P2093

Amy Frye-Anderson

http://www.w3.org/2001/XMLSchema#string

C Michael Stein

http://www.w3.org/2001/XMLSchema#string

Chun Li

http://www.w3.org/2001/XMLSchema#string

Dan M Roden

http://www.w3.org/2001/XMLSchema#string

Richard B Kim

http://www.w3.org/2001/XMLSchema#string

Scott M Dudek

http://www.w3.org/2001/XMLSchema#string

Ute I Schwarz

http://www.w3.org/2001/XMLSchema#string

Yuki Bradford

http://www.w3.org/2001/XMLSchema#string

P2860

Haploview: analysis and visualization of LD and haplotype maps

Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation

CYP2C9 allelic variants: ethnic distribution and functional significance

The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Hemorrhagic complications of anticoagulant treatment.

Common VKORC1 and GGCX polymorphisms associated with warfarin dose.

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.

The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.

Risk of major hemorrhage for outpatients treated with warfarin.

CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences.

P304

999-1008

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA0708078

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

358

http://www.w3.org/2001/XMLSchema#string

P50

Marylyn D. Ritchie

P577

2008-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18322281

http://www.w3.org/2001/XMLSchema#string

P921

anticoagulation

P932

3894627

http://www.w3.org/2001/XMLSchema#string